Anti-Human CD3-FITC/CD19-PE[OKT3,CB19]

Introducing the Anti-Human CD3-FITC/CD19-PE[OKT3,CB19], a cutting-edge product designed to revolutionize immunological research and diagnostics. This meticulously crafted reagent combines the power of two monoclonal antibodies, CD3-FITC and CD19-PE, to provide unparalleled specificity and accuracy in detecting human CD3 and CD19 antigens.

The Anti-Human CD3-FITC/CD19-PE[OKT3,CB19] is meticulously engineered using state-of-the-art technology, ensuring exceptional performance and reliability. Its unique formulation guarantees optimal binding affinity, enabling precise identification and quantification of CD3 and CD19 markers on human cells.

This product's exceptional fluorescence properties, with CD3-FITC emitting a vibrant green signal and CD19-PE emitting a striking red signal, facilitate effortless visualization and discrimination of CD3 and CD19 antigens. This enables researchers and clinicians to gain valuable insights into immune cell populations, aiding in the diagnosis and monitoring of various immunological disorders.

The Anti-Human CD3-FITC/CD19-PE[OKT3,CB19] is meticulously validated and quality-controlled to meet the highest industry standards. Its exceptional specificity ensures minimal cross-reactivity, guaranteeing accurate and reliable results. Furthermore, this reagent exhibits excellent stability, allowing for long-term storage without compromising its performance.

This product is compatible with a wide range of flow cytometry platforms, making it versatile and adaptable to various laboratory settings. Its user-friendly nature simplifies experimental procedures, saving valuable time and resources.

In summary, the Anti-Human CD3-FITC/CD19-PE[OKT3,CB19] is a cutting-edge immunological tool that offers unmatched precision and reliability in the detection and quantification of CD3 and CD19 antigens. With its exceptional performance, ease of use, and compatibility with various flow cytometry platforms, this reagent is an indispensable asset for researchers and clinicians alike, propelling advancements in immunological research and diagnostics.